0 (0%)		12-27 00:26
Open: High: Volume: 0		Pre. Close: Low: Market Cap: 0(M)

Short term
Mid term
Targets	6-month :	15.53	1-year :	18.14
Resists	First :	13.3	Second :	15.53
Pivot price	13.17
Supports	First :	13.02	Second :	12.85
MAs	MA(5) :	13.19	MA(20) :	13.18
	MA(100) :	13.05	MA(250) :	0
MACD	MACD :	-0.1	Signal :	-0.1
%K %D	K(14,3) :	83	D(3) :	78
RSI	RSI(14): 54
52-week	High :	13.44	Low :	12.4

Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.
[ NXC ] has closed below upper band by 25.8%. Bollinger Bands are 23.2% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

If tomorrow:	Open lower	Open higher
High:	13.3 - 13.37	13.37 - 13.42
Low:	13.06 - 13.13	13.13 - 13.19
Close:	13.12 - 13.23	13.23 - 13.32

Fri, 19 Dec 2025
NXP: Too Much Uncertainty To Recommend (NYSE:NXC) - Seeking Alpha

Tue, 09 Dec 2025
NXC buys back 151.2 bn won in treasury shares - 매일경제

Mon, 08 Dec 2025
Immix Soars On NXC-201 Data In Relapsed/Refractory AL Amyloidosis; BLA Planned For 2026 - Nasdaq

Sun, 07 Dec 2025
CAR T Cell Therapy for Light Chain (AL) Amyloidosis Achieves Strong Results - Memorial Sloan Kettering Cancer Center

Sun, 07 Dec 2025
At ASH 2025 Oral Presentation, Immix Biopharma Reports Positive Phase 2 NXC-201 Results, Advancing Toward BLA Submission as a Potentially First- and Best-in-Class Therapy for relapsed/refractory AL Amyloidosis - Yahoo Finance

Thu, 18 Sep 2025
Phase 1/2 Trial for Immix Biopharma’s AL Amyloidosis CAR T NXC-201 Hits Over 50% Enrollment - CGTLive®

Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.	Neutral
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).	Neutral
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.	Neutral
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.	Neutral
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.	Neutral
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.	Neutral

Exchange:
Sector:
Industry:
Shares Out	6 (M)
Shares Float	0 (M)
Held by Insiders	0 (%)
Held by Institutions	11.1 (%)
Shares Short	6 (K)
Shares Short P.Month	15 (K)

EPS	-0.39
EPS Est Next Qtrly	0
EPS Est This Year	0
EPS Est Next Year	0
Book Value (p.s.)	12.97
Profit Margin	-68.5 %
Operating Margin	90.8 %
Return on Assets (ttm)	2.4 %
Return on Equity (ttm)	-3 %
Qtrly Rev. Growth	-0.7 %
Gross Profit (p.s.)	0.57
Sales Per Share	0.57
EBITDA (p.s.)	0
Qtrly Earnings Growth	0 %
Operating Cash Flow	0 (M)
Levered Free Cash Flow	0 (M)

PE Ratio	-33.9
PEG Ratio	0
Price to Book value	1.01
Price to Sales	23.1
Price to Cash Flow	0

Dividend	0.03
Forward Dividend	0
Dividend Yield	0.3%
Dividend Pay Date	Invalid DateTime.
Ex-Dividend Date	Invalid DateTime.